Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder or Schizophrenia
2009-010276-16Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olanzapine in bipolar I disorder and schizophrenia, sponsored by Eli Lilly and Company. Primary endpoints: Safety evaluations and Change from baseline in BMI. Started Jun 2009; status: completed.
02
Drugs
olanzapine
03
Conditions
bipolar I disorderschizophrenia
Beyond the preview
Go deeper on 2009-010276-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010276-16.